These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 15964935)

  • 21. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
    Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A
    J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
    Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
    J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
    Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
    Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
    Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
    J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition.
    Dorn A; Hermann F; Ebneth A; Bothmann H; Trube G; Christensen K; Apfel C
    J Biomol Screen; 2005 Jun; 10(4):339-47. PubMed ID: 15964935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S; Lacroix P
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.